Chapel Hill, NC, United States of America

Hannah S White

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: G1 Therapeutics, Inc., Pharmacosmos Holding A/s, Gi Therapeutics, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hannah S White. Retrieved from https://idiyas.com/inventor/hannah-s-white

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

7 out of 48

G1 Therapeutics, Inc.

patents

4 out of 29

Pharmacosmos Holding A/s

patents

2 out of 8

Gi Therapeutics, Inc.

patents

Years Active: 2019-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534472 - Morphic forms of trilaciclib and methods of manufacture thereof (2026-01-27),

2. 12497404 - Morphic forms of trilaciclib and methods of manufacture thereof (2025-12-16),

3. 12479855 - Morphic forms of trilaciclib and methods of manufacture thereof (2025-11-25),

4. 12264135 - Synthesis of 1,4-diazaspiro[5.5]undecan-3-one (2025-04-01),

5. 12168666 - Morphic forms of trilaciclib and methods of manufacture thereof (2024-12-17),

6. 12139494 - Morphic forms of G1T38 and methods of manufacture thereof (2024-11-12),

7. 11708337 - Synthesis of 1,4-diazaspiro[5.5]undecan-3-one (2023-07-25),

8. 11629150 - Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines (2023-04-18),

9. 11446295 - Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors (2022-09-20),

10. 11261193 - Morphic forms of G1T38 and methods of manufacture thereof (2022-03-01),

11. 10988479 - Morphic forms of trilaciclib and methods of manufacture thereof (2021-04-27),

12. 10865210 - Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines (2020-12-15),

13. 10231969 - Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors (2019-03-19),

Title: The Innovative Contributions of Hannah S. White

Introduction

Hannah S. White is a prominent inventor based in Chapel Hill, NC, known for her significant contributions to the field of pharmaceuticals. With a total of nine patents to her name, she has made remarkable advancements in drug formulation and stability.

Latest Patents

Among her latest patents is the invention titled "Morphic forms of trilaciclib and methods of manufacture thereof." This patent describes an advantageous isolated morphic form of trilaciclib, specifically a di-hydrochloride salt or dihydrate, which enhances its therapeutic efficacy. Another notable patent is "Morphic forms of G1T38 and methods of manufacture thereof," which provides a highly crystalline form of the di-HCl salt, ensuring improved pharmaceutical efficacy and dosage form stability.

Career Highlights

Hannah has worked with leading companies in the pharmaceutical industry, including G1 Therapeutics, Inc. and Gi Therapeutics, Inc. Her work has focused on developing innovative solutions that address critical challenges in drug delivery and stability.

Collaborations

Throughout her career, Hannah has collaborated with esteemed colleagues such as Alexander Smith and Jay Copeland Strum. These partnerships have fostered a collaborative environment that has led to groundbreaking advancements in her field.

Conclusion

Hannah S. White's contributions to pharmaceutical innovation are noteworthy, with her patents reflecting her dedication to improving drug

Profile summary based on public USPTO records.